92 results about "Zonulin" patented technology

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

A method for prevention of delaying the onset of diabetes using peptide antagonists of zonulin, is disclosed.

The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.

Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.

A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).

Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.

Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing amount of one or more tight junction agonists. Tight junction agonists include zonulin and / or ZOT receptor agonists. Methods of the invention include orally administering compositions of the invention.

The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in exosomes from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2 or any combination of two or more of these proteins.

Provided herein are fusion proteins including at least one binding polypeptide and at least one unstructured polypeptide. The fusion protein may further include at least one linker. Further provided are methods for determining the presence of a target in a sample, methods of treating a disease, methods of diagnosing a disease in a subject, and methods of determining the effectiveness of a treatment for a disease in a subject. The methods may include administering to the subject an effective amount of the fusion protein.

The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist.

A composition for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, pathological ocular neovascularization comprises an integrin or vitronectin receptor antagonist having any one of Formulae I-XI, as defined herein. The composition can further comprise a VEGF inhibitor. Such composition is administered to an ocular environment by a method such as topical application, periocular injection, intravitreal injection, or intravitreal implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment.

The invention discloses a fusion protein for Micrococcus pyogenes surface protein, and also discloses the method for preparing the same as well as its usage. The fusion protein is fused by Micrococcus pyogenes fnb and thioredoxin Trx on expression carrier, and the process comprises preparation of Micrococcus pyogenes surface protein fnb coding gene, colony of fnb coding gene into expression carrier and protein fusion. The fusion protein is soluble protein and retains immunity of natural protein. It is detected that said fusion protein is characterized by good response for humoral immunity and cell immunity, enlargement of protection range of protein vaccine and prevention of infection caused by most of Micrococcus pyogenes.

Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

An isolated, altered fibronectin-binding protein (Fnb) of S. aureus having at least one mutation in an amino acid selected from residues corresponding to Gln103, Gln105, Lys157, Lys503, Lys620, Lys702, Lys762, Gln783 and Gln830 of FnbA of S. aureus strain ATCC49525 is described. Replacement of these reactive residues within the fibronectin-binding protein renders this protein less capable than wild-type Fnb of covalently cross-linking with fibronectin and fibrin. The altered fibronectin-binding protein effectively interferes with adhesion of S. aureus to fibronectin and fibrin, and therefore, an immunogenic composition comprising such altered Fnb exhibits improved immunogenic properties and is safer to use.

The invention relates to the medical field of immunoassay, more specially, the invention provides a laminin detection kit and a preparation method thereof. The kit of the invention comprises 1) a laminin calibrator, 2) an avidin-coated vector, 3) a mixture of a biotinylation laminin monoclonal antibody and a laminin polyclonal antibody or a monoclonal antibody enzyme marker, 5) a chemiluminescent substrate and 6) a concentrated washing solution. Further, the preparation method of the kit according to the invention comprises the following steps: 2) preparing the calibrator with laminin, 2) coating the vector with avidin, 3) biotinylating the laminin monoclonal antibody, 4) marking the laminin polyclonal antibody or monoclonal antibody with the enzyme, 5) preparing the chemiluminescent substrate, 6) preparing the concentrated washing solution, 7) packaging the calibrator, the biotinylation laminin, the chemiluminescent sustrate and the concentrated washing solution, and 8) assembling finished products. The kit of the invention has the advantages of simplicity, convenience, sensitivity, stability and the like, and provides a valuable detection means for clinic diagnosis and scientific research.

The present application relates to urinary protein markers for chronic pancreatitis and uses thereof. Specifically, this application relates to the use of urine protein markers obtained by using chronic pancreatitis disease models and mass spectrometry analysis in the early diagnosis of human chronic pancreatitis disease and the use of disease course monitoring. The urine protein markers are selected from Igγ‑1 chain C domain, nucleonectin‑2, beta‑2‑microglobulin, interleukin‑4 receptor alpha subunit, phosphoglycerate mutase 1, dipeptidyl peptidase 2, secreted pyrophosphoprotein 24, glycans Core protein, endothelial cell selective adhesion molecule, nestin-2, serum amyloid substance p, nerve cell adhesion molecule 1, etc. In this application, the obtained differential protein in urine provides a non-invasive and convenient option for early diagnosis and subsequent treatment of chronic pancreatitis.

The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2).

The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist.

The invention relates to prostatic cancer markers from a prostatic secretion, and discloses a group of new prostatic cancer markers comprising Haptoglobin alpha-chains, Fibronectin1, Albumin and / or SERPINB1. In the prostatic secretion, the expression of the above proteins in prostatic cancer patients is substantially higher than the expression in non-cancer patients, so reagents or kits for the diagnosis, the assessment and the prognosis of the prostatic cancer can be developed based on the proteins.

The invention discloses a Mycoplasma bovis alcohol dehydrogenase gene, having a nucleotide sequence shown as SEQ ID NO: 1. The invention also discloses a protein coded by the Mycoplasma bovis alcohol dehydrogenase gene; the protein has an amino acid sequence shown as SEQ ID NO: 2 and belongs to the technical field of prevention and treatment of animal infectious diseases and biology. The protein, as a recombinant protein herein, has alcohol dehydrogenase activity, can attach to EBLs (embryonic bovine lung cells), can combine with bovine Fn (fibronectin), has good immunogenicity and reactogenicity, is a virulence-related protein of Mycoplasma bovis, and has a good application prospect in the research on pathogenesis of Mycoplasma bovis, and the research and development of vaccines and diagnostic reagents.

The invention discloses a biological protective covering and a preparation method thereof. The biological protective covering is made of a substrate namely animal intestinal membranes, which have been crosslinked and fixed by a non-aldehyde fixing agent and subjected to an antigen removal treatment. An active modification layer, which contains fibronectin, laminin, or vitronectin that can adhere to cells, or an antibacterial sustained-release layer containing antibacterial drugs is arranged on the surface of the substrate. The biological protective covering is made of thin and tough animal intestinal membranes, and is light, soft, and user-friendly. The intestinal membranes are semi-permeable, gas and steam can penetrate the intestinal membranes, but bacteria cannot go through the intestinal membranes. Moreover, the intestinal membranes have been subjected to a multi-aspect antigen removal treatment to effectively remove the immunogenicity, the surface is subjected to active modification, the surface can aggregate epithelial cells and fibroblast to promote wound healing; the antibacterial drugs can be sustained-released, the anti-infection effect is enhanced, and the using performance and protective effect are better than those of dressing or protective covering made of pig skin.

The invention discloses a recombinant human fibronectin III1-C (rhFNIII1-C), and a preparation method and application thereof. The preparation method comprises the following steps: optimizing a targetgene segment of the target protein according to codon expression preference, and inserting the obtained gene segment into pET-32a to construct a recombinant plasmid; transforming and introducing therecombinant plasmid into an expression vector BL21(DE3), and carrying out screening to obtain positive clone bacteria capable of realizing efficient soluble expression; carrying out enlarging fermentation culture on the positive clone bacteria, carrying out induced expression, performing crushing and centrifuging to obtain a supernatant, and carrying out purification through elution with a His-tagaffinity chromatography column, dialysis, filtration and other steps to obtain a high-quality rhFNIII 1-C solution with a protein concentration of 1.0 mg / mL or above and a purity of 90% or above. According to detection and observation results of cell adhesion promoting tests, the rhFNIII1-C has the performance of obviously promoting adherence and adhesion of MDBK cells and Balb / c / 3T3 cells and rapid division and growth of the cells, which indicates that the rhFNIII1-C has huge potential of being used as a raw material and a finished product for cosmeceuticals and medical skincare.

The invention relates to polypeptide face-firming repairing essence and a preparation method thereof. The essence is prepared from the following components of, according to the following percentage, 8% of butanediol, 1% of betaine, 0.9% of glyceryl polyacrylate, 1.1% of glycerinum, 2% of lactobacillus, 2% of rice fermentation products, 1% of radix ginseng rubra (PANAXGINSENG) extract, 0.5% of 3-o-ethyl ascorbic acid, 0.4% of acetyl hexapeptide-8, 0.4% of palmitoyl pentapeptide-4, 0.3% of fullerene, 0.3% of decapeptide-4, 0.3% of glycoprotein, 0.3% of fibronectin, 0.3% of bifida ferment lysate, 0.3% of peony (PAEONISASUFFRUTICOSA) root extract, 0.2% of arginine, 0.2% of lactobacillus ferment lysate, 0.2% of hydrolyzed collagen, 0.2% of euglena gracilis (EUGLENAGRACILIS) polysaccharide, 0.2% of radix gentianae (GENTIANASCABRA) extract, 0.2% of chlorella vulgaris (CHLORELANACABRA) extract, 0.2% of crocus sativus (CROCUSSATIVUS) extract, 0.2% of caprylhydroxamic acid and the balance water. The essence has an obvious moisturizing effect, can be used for a long time, has no side effect, is good in effective component extracting effect, and is suitable for industrial production.